Search results
Showing 3556 to 3570 of 8236 results
Embed NICE content in your digital products and services with our syndication API.
Using our content internationally. Includes information on fees and licensing agreements for both AI and non AI requests.
Using NICE content for AI purposes. Includes complete content, adaptation, contextualisation, translation, selected extracts and the use of our COVID-19 content internationally.
Learn more about what NICE content is available for reuse by checking our information asset register.
Learn about situations where you cannot use NICE content.
Find out how and where you can reuse NICE's content. Includes use of our content in the UK, use of our content internationally, use of our content for AI purposes, our content assurance process, and our information asset register.
Research to access pathway for investigational drugs for COVID-19 (RAPID C-19)
RAPID C-19’s role in reviewing potential COVID-19 treatments has now ended because we have moved back to routine commissioning arrangements for these treatments.
How we collect and use your personal information, and your rights under data protection legislation.
Our guidelines make evidence based, best practice recommendations. These help to improve patient safety and reduce the risk of harm across the health system.
Subscribe to NICE newsletters and alerts for the latest healthcare guidance, clinical updates, and evidence-based resources across health and social care.
NICE's decisions on how we prioritise topics, by year.
Our centralised approach to prioritising our guidance topics ensures that we produce guidance that's relevant, timely, accessible, and has demonstrable impact.
Our centralised approach to prioritising our guidance topics ensures that we produce guidance that's relevant, timely, accessible, and has demonstrable impact.
Each year we work with NHSE and the DHSC to prioritise topics for development.
Our centralised approach to prioritising guidance topics ensures that we produce guidance that is relevant, timely, accessible, and has demonstrable impact.